Our work addresses these challenges through two key innovations: First, we demonstrate that exogenous cystine supplementation bypasses intrinsic SLC7A11 dependency, enabling robust disulfidptosis in SLC7A11 low/intermediate neuroblastomas under glucose-deprived conditions. Here, SLC7A11 is linked to neuroblastoma.